Legal Cannabis and CBD-Based Products Projected to Gain Popularity

Wednesday, June 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

FinancialBuzz.com News Commentary

NEW YORK, June 28, 2017 /PRNewswire/ --

According to a recent report

by New Frontier Data, the Viridian Cannabis Stock Index gained 236.1% in 2016, or outperforming such mainstream indexes as the Russell 2000 (up 19.5%), the Dow Jones Industrial Average (up 13.4%), the S&P 500 (up 9.5%), and the Nasdaq composite (up
7.5%). Businesses that touch the plant and in ancillary sector, helps to show the data growth in 2016 of underlying sectors in the cannabis markets. New Frontier Data also indicates that in 2017, medical cannabis sales are forecast to grow to $5.3 billion, or accounting for 67% of total cannabis sales. By 2025, medical sales in currently legal states are forecast to grow to $13.2 billion, at this point medical sales will account for 55% of all sales. Comparatively, adult-use sales in 2017 are forecast to reach $2.6 billion, or rising to $10.9 billion by 2025. ChineseInvestors.com, Inc. (OTC: CIIX), Cannabis Sativa, Inc. (OTC: CBDS), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Insys Therapeuticsis Inc. (NASDAQ: INSY), Cara Therapeutics Inc. (NASDAQ: CARA).

A major portion of the legal cannabis market is the Hemp and CBD market. Sean Murphy, the Founder and Publisher of Hemp Business Journal explained, "Hemp Business Journal estimates the total retail value of all hemp products sold in the U.S. to be at least $688 million for 2016. We estimate the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products. The data demonstrates the hemp industry is growing quickly at 22% five year CAGR and being led by food and body care products, with Hemp CBD products showing a 53% AGR."

ChineseInvestors.com, Inc. (OTCQB: CIIX) just announced earlier today that its wholly owned foreign enterprise, CBD Biotechnology Co. Ltd., will officially launch its first line of non-industrial hemp infused skin care products, the 'CBD Magic Hemp Series'. The product line will include four products, namely, CBDBIO TECH Toner, CBDBIO TECH Rejuvenating Cream, and CBDBIO TECH Perfecting Shield Primer and CBDBIO TECH Rejuvenating Spray.

The new skin care line is expected to be launched in this quarter of 2017. CBD Biotechnology Co. Ltd. plans to use multiple sales channels to implement its sales plan including Tmall, TaoBao, the Company's official website, broadcasting platforms of internet celebrities, mobile news applications, and a multi-level direct selling system in cooperation with Shangdong Yibao Biologics Co. Ltd.

"Following the launch of OptHemp Ultra Premium Hemp Oil by CIIX's wholly owned U.S. subsidiary, ChineseHempOil.com, Inc., I am very pleased to announce the launch of CBD Biotechnology Co., Ltd. non-industrial hemp infused skin care line," says Summer Yun, CEO of CBD Biotechnology Co., Ltd. "CBD Biotechnology Co., Ltd. will be one of the first companies in China to incorporate hemp-based CBD into skin care products, which we believe will spark public interest."

"An estimated 55,700 metric tons of industrial hemp are produced around the world each year with China, Russia, and South Korea leading in production, accounting for 70 percent of the world's industrial hemp supply. Although China is one of the leading producers of industrial hemp, the benefits to the human body have not yet been widely recognized in mainland China," says Yun. "As one of the companies to introduce a skin care line infused with hemp-based CBD to China, CIIX looks forward to educating the almost 1.4 billion people in China about the benefits of hemp-based CBD and the positive effects it can have on the largest, visible human organ - the skin."

On April 10, 2017, Cannabis Sativa, Inc. (OTCQB: CBDS) announced that it entered into an agreement to acquire the intellectual property for the White Rabbit brand of cannabis sprays and cannabis mints. The White Rabbit product line currently consists of fast acting low dose cannabis oral sprays and popular low dose cannabis mints. Both the spray and the mints are formulated as CBD only, THC only and CBD/THC blends. Dosage ranges include 2.5mg, 5mg and 10mg tablets and sprays with 1:1 and 20:1 variations of each. The Company's President David Tobias stated, "The White Rabbit line of products is very attractive to us given its low dose and metering, which are important qualities for medicinal use."

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. The company recently announced that it has met its enrollment target of 16 patients in its Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in children with Fragile X syndrome (FXS). ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS.

Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys Therapeuticsis Inc. (NASDAQ: INSY) is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Earlier in May, the company announced that the U.S. Food and Drug Administration ('FDA') has approved the final product label for Syndros™ (dronabinol) oral solution, CII, a liquid formulation of the pharmaceutical cannabinoid, dronabinol. Syndros is approved for use in treating anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome ('AIDS') and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Cara Therapeutics Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Cara's most advanced CB compound, CR701, is in preclinical development. Dr. Joseph Stauffer, CMO Cara Therapeutics, said, "Cannabinoid Receptor Agonists like CR701 have the potential to provide improved pain relief for patients suffering from neuropathic pain."

Please Sign Up Now at http://www.FinancialBuzz.com to receive alerts on trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE: https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and PR services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com. For further information: Media Contact: [email protected]   +1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store